Cosmo Pharmaceuticals N.V. (CMOPF)
USD 73.5
(0.0%)
USD 73.5
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -48.43 Million EUR | -769.65% |
| 2022 | -5.56 Million USD | 77.33% |
| 2021 | -24.56 Million USD | -86.23% |
| 2020 | -13.19 Million USD | -121.58% |
| 2019 | 61.12 Million USD | 201.77% |
| 2018 | -60.05 Million EUR | 64.39% |
| 2017 | -168.67 Million EUR | -42.35% |
| 2016 | -118.49 Million EUR | -72.75% |
| 2015 | -68.59 Million EUR | -195.55% |
| 2014 | -23.2 Million EUR | 32.91% |
| 2013 | -34.59 Million EUR | -139.13% |
| 2012 | -14.46 Million EUR | -26.35% |
| 2011 | -11.44 Million EUR | 53.94% |
| 2010 | -24.85 Million EUR | -75.21% |
| 2009 | -14.18 Million EUR | 20.63% |
| 2008 | -17.87 Million EUR | 11.99% |
| 2007 | -20.3 Million EUR | -668.35% |
| 2006 | 3.57 Million EUR | -82.88% |
| 2005 | 20.87 Million EUR | 9.48% |
| 2004 | 19.06 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -53.7 Million EUR | -10.88% |
| 2024 Q2 | -53.1 Million EUR | 1.12% |
| 2023 Q2 | 69.58 Million USD | 24.15% |
| 2023 FY | -48.43 Million EUR | -769.65% |
| 2023 Q1 | 56.05 Million EUR | 1106.35% |
| 2023 Q3 | -49.19 Million EUR | -170.7% |
| 2023 Q4 | -48.43 Million EUR | 1.54% |
| 2022 Q4 | -5.56 Million USD | 57.1% |
| 2022 FY | -5.56 Million USD | 77.33% |
| 2022 Q1 | -51.97 Million EUR | -81.46% |
| 2022 Q2 | -48.36 Million EUR | 6.96% |
| 2022 Q3 | -12.98 Million EUR | 73.15% |
| 2021 Q1 | -15.66 Million EUR | 11.94% |
| 2021 FY | -24.56 Million USD | -86.23% |
| 2021 Q2 | -12.29 Million EUR | 21.56% |
| 2021 Q3 | -34.05 Million EUR | -177.03% |
| 2021 Q4 | -28.64 Million EUR | 15.88% |
| 2020 Q4 | -17.79 Million EUR | 26.33% |
| 2020 FY | -13.19 Million USD | -121.58% |
| 2020 Q2 | 85.42 Million EUR | -6.09% |
| 2020 Q3 | -24.15 Million EUR | -128.27% |
| 2020 Q1 | 90.97 Million EUR | 67.07% |
| 2019 Q3 | 57.85 Million EUR | 998.67% |
| 2019 FY | 61.12 Million USD | 201.77% |
| 2019 Q1 | 4.3 Million EUR | 108.2% |
| 2019 Q2 | 5.26 Million EUR | 22.22% |
| 2019 Q4 | 54.45 Million EUR | -5.89% |
| 2018 FY | -60.05 Million EUR | 64.39% |
| 2018 Q3 | -61.45 Million EUR | 23.25% |
| 2018 Q2 | -80.07 Million EUR | 19.21% |
| 2018 Q1 | -99.12 Million EUR | 29.43% |
| 2018 Q4 | -52.53 Million EUR | 14.51% |
| 2017 Q4 | -140.46 Million EUR | 15.63% |
| 2017 Q2 | -131.38 Million EUR | 6.67% |
| 2017 Q1 | -140.77 Million EUR | -25.31% |
| 2017 FY | -168.67 Million EUR | -42.35% |
| 2017 Q3 | -166.49 Million EUR | -26.73% |
| 2016 Q4 | -112.34 Million EUR | 11.55% |
| 2016 Q2 | -66.82 Million EUR | 14.09% |
| 2016 Q1 | -77.78 Million EUR | -23.2% |
| 2016 FY | -118.49 Million EUR | -72.75% |
| 2016 Q3 | -127.01 Million EUR | -90.07% |
| 2015 Q2 | -32.17 Million EUR | 10.84% |
| 2015 FY | -68.59 Million EUR | -195.55% |
| 2015 Q4 | -63.14 Million EUR | 12.4% |
| 2015 Q3 | -72.08 Million EUR | -124.06% |
| 2015 Q1 | -36.08 Million EUR | -55.47% |
| 2014 FY | -23.2 Million EUR | 32.91% |
| 2014 Q4 | -23.2 Million EUR | 25.24% |
| 2014 Q3 | -31.04 Million EUR | -73.45% |
| 2014 Q2 | -17.89 Million EUR | 32.55% |
| 2014 Q1 | -26.53 Million EUR | 23.29% |
| 2013 Q3 | -48.61 Million EUR | 41.07% |
| 2013 FY | -34.59 Million EUR | -139.13% |
| 2013 Q4 | -34.59 Million EUR | 28.85% |
| 2013 Q2 | -82.49 Million EUR | 23.17% |
| 2013 Q1 | -107.37 Million EUR | -642.29% |
| 2012 Q4 | -14.46 Million EUR | 0.0% |
| 2012 Q2 | -30.11 Million EUR | 0.0% |
| 2012 FY | -14.46 Million EUR | -26.35% |
| 2011 Q2 | -22.81 Million EUR | 0.0% |
| 2011 FY | -11.44 Million EUR | 53.94% |
| 2011 Q4 | -11.44 Million EUR | 0.0% |
| 2010 Q2 | -27.16 Million EUR | 0.0% |
| 2010 Q4 | -24.85 Million EUR | 0.0% |
| 2010 FY | -24.85 Million EUR | -75.21% |
| 2009 FY | -14.18 Million EUR | 20.63% |
| 2009 Q4 | -14.18 Million EUR | 0.0% |
| 2008 FY | -17.87 Million EUR | 11.99% |
| 2007 FY | -20.3 Million EUR | -668.35% |
| 2006 FY | 3.57 Million EUR | -82.88% |
| 2005 FY | 20.87 Million EUR | 9.48% |
| 2004 FY | 19.06 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AstraZeneca PLC | 22.74 Billion USD | 100.213% |
| Bristol-Myers Squibb Company PFD CONV 2 | 30 Billion USD | 100.161% |
| CSPC Pharmaceutical Group Limited | -1.59 Billion USD | 96.961% |
| Clarus Therapeutics Holdings, Inc. | 15.85 Million USD | 405.513% |
| Novartis AG | 12.95 Billion USD | 100.374% |
| PT Kalbe Farma Tbk. | -169.7 Million USD | 71.458% |